MEN'S ROGAINE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for MEN'S ROGAINE (MEN'S ROGAINE).
Minoxidil is a potassium channel opener that increases cutaneous blood flow and stimulates hair follicles through vasodilation and direct mitogenic effects on dermal papilla cells, prolonging the anagen phase and increasing hair follicle size.
| Metabolism | Minoxidil is primarily metabolized by conjugation with glucuronic acid (via UGT1A1) to form minoxidil N-glucuronide; also undergoes sulfation and minor oxidative metabolism. |
| Excretion | Approximately 60% of topical minoxidil is absorbed systemically. The absorbed dose is primarily excreted via the kidneys as unchanged minoxidil and its glucuronide and sulfate conjugates. Renal excretion accounts for about 95% of elimination, with fecal excretion (~5%) being minor. Unabsorbed drug is eliminated in feces via desquamation and washing. |
| Half-life | The terminal elimination half-life of minoxidil after topical administration is approximately 4.2 hours (range 2.5–4.7 hours) in patients with normal renal function. This short half-life necessitates twice-daily application to maintain steady-state concentrations for continuous hair growth stimulation. |
| Protein binding | Minoxidil is approximately 20% bound to plasma proteins (primarily albumin). Binding is low and not concentration-dependent over the therapeutic range. |
| Volume of Distribution | The apparent volume of distribution (Vd) of minoxidil after intravenous administration is approximately 3.3 L/kg (range 2.5–4.2 L/kg), indicating extensive distribution into tissues. This large Vd is consistent with its lipophilicity and penetration into hair follicles and skin. |
| Bioavailability | Bioavailability of minoxidil from topical 5% solution is approximately 1.5% (range 0.3–4.5%) of the applied dose, based on urinary recovery. The 2% solution yields similar relative bioavailability (about 1.4%). Systemic absorption is minimal, with most drug remaining in the skin and hair follicles. |
| Onset of Action | Onset of clinical effect (visible hair regrowth) occurs after approximately 2–4 months of twice-daily topical application (5% solution). Some patients may notice early signs (vellus hair) at 2 months, but cosmetically meaningful results typically require 4–6 months. With the 2% solution, onset may be slightly delayed (4–6 months). |
| Duration of Action | Duration of action is dependent on continued application: hair regrowth is maintained as long as treatment is continued. Discontinuation leads to reversal of effect within 3–6 months (hair loss returns to pretreatment state). The pharmacodynamic effect persists for the duration of dosing interval (12 hours) but sustained therapeutic benefit requires continuous twice-daily use. |
Topical 5% solution: apply 1 mL to scalp twice daily. Max: 2 mL/day.
| Dosage form | AEROSOL, FOAM |
| Renal impairment | No dose adjustment required for topical use; systemic absorption minimal. |
| Liver impairment | No dose adjustment required for topical use; systemic absorption minimal. |
| Pediatric use | Safety and efficacy not established in patients under 18 years; not recommended. |
| Geriatric use | No specific dose adjustment; use same as adults but monitor for systemic effects due to possible skin atrophy and reduced renal function. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for MEN'S ROGAINE (MEN'S ROGAINE).
| Breastfeeding | Minoxidil is excreted into breast milk in low amounts; the milk-to-plasma (M/P) ratio is unknown. Systemic absorption from topical application is minimal (approximately 1.4-2%), but due to potential adverse effects (e.g., hypotension) in the nursing infant, it is generally not recommended during breastfeeding. |
| Teratogenic Risk | Topical minoxidil (MEN'S ROGAINE) has limited systemic absorption; however, based on animal studies and case reports, it is classified as Pregnancy Category C. First trimester: No adequate human studies; animal studies show some fetal abnormalities at high doses. Second and third trimesters: Theoretical risk of fetal hypotension and altered hair growth; avoid use unless potential benefit outweighs risk. |
■ FDA Black Box Warning
None
| Serious Effects |
Hypersensitivity to minoxidil or any component of the formulation; use in women (not indicated); use in patients with pheochromocytoma; application to a shaved or damaged scalp.
| Precautions | May cause hypotension if absorbed systemically; avoid use on broken or irritated scalp; discontinue if scalp irritation, redness, or burning occurs; not effective for receding hairlines; palpitations, edema, or dizziness may indicate systemic absorption; use caution in patients with cardiovascular disease or hypertension. |
Loading safety data…
| Fetal Monitoring | No specific monitoring is routinely required for topical use due to low systemic absorption. However, in cases of accidental ingestion or extensive use, monitor maternal blood pressure, heart rate, and signs of fluid retention. Fetal monitoring is not indicated unless systemic toxicity occurs. |
| Fertility Effects | There are no known adverse effects of topical minoxidil on fertility in men or women. Systemic effects from topical application are negligible. |